Cellular therapy in tuberculosis

Shreemanta K Parida; Rajhmun Madansein; Nalini Singh; Nesri Padayatchi; Iqbal Master; Kantharuben Naidu; Alimuddin Zumla; Markus Maeurer

doi:10.1016/j.ijid.2015.01.016

Cellular therapy in tuberculosis

Int J Infect Dis. 2015 Mar:32:32-8. doi: 10.1016/j.ijid.2015.01.016.

Authors

Shreemanta K Parida¹, Rajhmun Madansein², Nalini Singh³, Nesri Padayatchi⁴, Iqbal Master⁵, Kantharuben Naidu⁶, Alimuddin Zumla⁷, Markus Maeurer⁸

Affiliations

¹ Therapeutic Immunology Division, Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: Shreemanta.Parida@ki.se.
² Department of Cardiothoracic Surgery, Inkosi Albert Luthuli Hospital, Dept of Health, KwaZulu-Natal province, Durban, South Africa; DR-TB Department, King Dinuzulu Hospital, Dept of Health, KwaZulu-Natal Province, Durban, South Africa; Centre for AIDS Prevention Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. Electronic address: rajhmun.madansein@ki.se.
³ DR-TB Department, King Dinuzulu Hospital, Dept of Health, KwaZulu-Natal Province, Durban, South Africa; MSC_Durban Team. Electronic address: nalini.singh@ki.se.
⁴ Centre for AIDS Prevention Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; MSC_Durban Team. Electronic address: Nesri.Padayatchi@caprisa.org.
⁵ DR-TB Department, King Dinuzulu Hospital, Dept of Health, KwaZulu-Natal Province, Durban, South Africa; MSC_Durban Team. Electronic address: iqbal.master@kznhealth.gov.za.
⁶ DR-TB Department, King Dinuzulu Hospital, Dept of Health, KwaZulu-Natal Province, Durban, South Africa; MSC_Durban Team. Electronic address: Ruben.Naidu@kznhealth.gov.za.
⁷ Division of Infection and Immunity, University College London, and NIHR Biomedical research centre at UCLHospitl, London, United Kingdom. Electronic address: a.i.zumla@gmail.com.
⁸ Therapeutic Immunology Division, Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Center for allogeneic stem cell transplantation (CAST), Karolinska Hospital, Stockholm, Sweden. Electronic address: markus.maeurer@ki.se.

PMID: 25809753
DOI: 10.1016/j.ijid.2015.01.016

Abstract

Cellular therapy now offer promise of potential adjunct therapeutic options for treatment of drug-resistant tuberculosis (TB). We review here the role of Mesenchymal stromal cells, (MSCs), as well as other immune effector cells in the therapy of infectious diseases with a focus on TB. MSCs represent a population of tissue-resident non-hematopoietic adult progenitor cells which home into injured tissues increase the proliferative potential of broncho-alveolar stem cells and restore lung epithelium. MSCs have been shown to be immune-modulatory and anti-inflammatory mediated via cell-cell contacts as well as soluble factors. We discuss the functional profile of MSCs and their potential use for adjunct cellular therapy of multi-drug resistant TB, with the aim of limiting tissue damage, and to convert unproductive inflammatory responses into effective anti-pathogen directed immune responses. Adjunct cellular therapy could potentially offer salvage therapy options for patients with drug-resistant TB, increase clinically relevant anti-M.tuberculosis directed immune responses and possibly shorten the duration of anti-TB therapy.

Keywords: HDT; M.tuberculosis; MDR-TB; Mesenchymal stromal cells; T-cells; Tuberculosis; cancer; host directed therapy; inflammation.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cell Transplantation
Humans
Infections / therapy
Mesenchymal Stem Cell Transplantation*
Mycobacterium tuberculosis / immunology
Tuberculosis, Multidrug-Resistant / immunology
Tuberculosis, Multidrug-Resistant / therapy*